Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in
angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1
Proto-Oncogene, Serine/Threonine Kinase (RAF1) and BRAF) and tumour growth (PDGFR and FGFR).
Epithelial ovarian cancer (EOC) cell lines frequently express high levels of vascular
endothelial growth factor (VEGF) and in vivo preclinical studies evaluating Regorafenib have
shown promising activity in ovarian cancer. In the clinic, anti-angiogenesis therapy with
bevacizumab (a monoclonal antibody to VEGF) has already emerged as an important cornerstone
in the management of ovarian cancer both as part of frontline adjuvant treatment and as
second-line therapy for platinum-sensitive recurrent disease. Whilst Regorafenib has been FDA
approved for the treatment of patients with metastatic colorectal cancer who have failed
prior bevacizumab, it's role in the management of ovarian cancer remains to be defined.